Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: A report of 80 cases

Cong Zeng1,2,3,4, Yan Chen1,2,3,4, Juan Hua1,2,3,4, Yi Liu1,2,3,4, Ting-ting Cheng1,2,3,4, Xia Ma1,2,3,4, Xu Chen1,2,3,4, Shi-yu Wang1,2,3,4 and Ya-jing Xu1,2,3,4*

1Department of Hematology, Xiangya Hospital, Central South University, Changsha, China, 2National Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Changsha, China, 3Hunan Hematologic Neoplasms Clinical Medical Research Center, Xiangya Hospital, Central South University, Changsha, China, 4National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Changsha, China

The outcomes of 80 patients with hematologic malignancies who received haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) combined with unrelated cord blood (UCB) from March 2017 to June 2020 were analyzed in this retrospective study. Anti-thymocyte globulin (ATG) was administered at a dose of 7.5 mg/kg. The median time for neutrophil and platelet engraftment was 13(range: 8-22) days and 14(range: 8-103) days, respectively. The 30-day cumulative incidence of neutrophil engraftment was 100%, and the 100-day cumulative incidence of platelet engraftment was 95%. All patients achieved complete haploidentical peripheral blood stem cell engraftment, and no cord blood chimerism was observed. The cumulative incidence of grades II-IV and grades III-IV acute graft-versus-host disease (aGVHD) on 100-day was 26.3%(95%CI: 17.2%–36.3%) and 5.0%(95%CI: 1.6%–11.4%), respectively. The estimated cumulative incidence of chronic GVHD (cGVHD) and moderate-severe cGVHD at 3-year was 43.3%(95%CI: 31.6%–54.4%) and 16.0%(95%CI: 8.7%–25.2%), respectively. The estimated 3-year cumulative incidence of relapse and non-relapse mortality was 18.8%(95%CI: 10.0%–29.7%) and 17.8%(95%CI: 9.9%–27.5%), respectively. The estimated 3-year probabilities of overall survival, disease-free survival, GVHD/relapse-free survival were 77.6%(95%CI: 68.3%–88.1%), 63.4%(95%CI: 52.6%–76.5%), and 55.5%(95%CI: 44.8%–68.7%), respectively. These satisfying results suggested that haplo-PBSCT combined with UCB is an alternative transplantation protocol for hematologic malignancies.

KEYWORDS
peripheral blood, cord blood, haploidentical donor, allogeneic hematopoietic stem cell transplantation, hematologic malignancy
**Introduction**

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the leading therapy for hematologic malignancies. Haploidentical HSCT (haplo-HSCT) is an alternative for patients who require urgent transplantation but do not have a matched sibling donor (MSD). In recent years, the number of haplo-HSCT has increased rapidly worldwide due to the development of T-cell depletion (TCD) protocol (1, 2). Currently, three dominant TCD protocols are used in haplo-HSCT: in vivo TCD protocol with posttransplant cyclophosphamide (PTCY), in vitro TCD protocol, and in vivo TCD protocol with granulocyte colony-stimulating factor (G-CSF) and anti-thymocyte globulin (ATG) (termed as “Beijing protocol”). The PTCY-based haploidentical transplantation protocol is widely used in Europe and USA; it usually uses peripheral blood stem cells (PBSCs) as the graft source. Several studies have compared the efficacy of PB grafts and bone marrow (BM) grafts in haplo-HSCT using PTCY, indicating faster engraftment and higher incidence of graft-versus-host disease (GVHD) in PB compared to BM grafts, but no significant difference was detected in the long-term survival between the two groups (3–5). "Beijing protocol" is a G-CSF/ATG-based haploidentical BM plus PB transplantation protocol was established by Huang et al. The standard ATG dose is 10 mg/kg in “Beijing protocol.” By 2019, “Beijing protocol” accounted for 94% of haplo-HSCT in China (1). A prospective study found comparable outcomes but rapid hematopoietic reconstitution in G-CSF/ATG-based haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) compared to “Beijing protocol;” however, the incidence of GVHD was generally high in this study (6). Nonetheless, only a few studies have explored this protocol, thereby necessitating need multicenter, prospective, randomized trials to confirm the outcomes.

Cord blood is another widely used source of grafts. The incidence of GVHD in cord blood transplantation is low, but the limited cell count results in delayed hematopoietic reconstruction (7). In order to achieve both rapid hematopoietic reconstitution and a low incidence of GVHD, some studies have combined haplo-HSCT with unrelated cord blood (UCB) and found that this protocol provides the advantages of both methods (8–10). However, the source of stem cells in most of these studies was BM plus PB combined with UCB, and only a few studies utilized pure PB combined with UCB. Therefore, we attempted to use UCB to assist haplo-PBSCT, which avoids the risks of general anesthesia and the pain of bone marrow collection in the donor, thereby easing the operation. Also, the dose of ATG was reduced to 7.5 mg/kg due to the addition of UCB. Finally, we analyzed the outcomes of 80 patients with hematologic malignancies who received haplo-PBSCT combined with UCB (haplo-cord-PBSCT) at the Department of Hematology, Xiangya Hospital of Central South University between March 2017 and June 2020.

**Patients and methods**

**Patients**

A total of 80 patients with hematologic malignancies who received haplo-cord-PBSCT were retrospectively analyzed in this study from March 2017 to June 2020. Patients who met the following inclusion criteria were recruited in this study: 1. Acute leukemia (AL) diagnosis according to World Health Organization (WHO) diagnostic criteria, with risk stratification according to NCCN guidelines; myelodysplastic syndrome (MDS) diagnosis according to FAB classification, with risk stratification referring to the International Prognostic Scoring System (IPSS); refractory relapse patients were defined as high-risk patients. 2. Patients receiving haplo-cord-PBSCT. 3. No severe impairment of the liver, kidney, lung, and cardiac function. All patients voluntarily signed the informed consent forms that were reviewed by our hospital ethics committee.

**Donors and cord blood selection**

HLA typing was assessed in both donors and recipients at a high resolution. Before transplantation, the HLA antibodies were tested in all patients, and donor-specific antibodies (DSA) were negative or weakly positive (MFI<4000) in all patients. The weakly-positive patients were not treated with plasmapheresis or rituximab. HLA-A, -B, -C, -DRB1, -DQB1 locus of UCB were detected at a high resolution. The DSA of cord blood was negative. UCB should be selected according to the following criteria: (1) >5/10 HLA-matching locus, and at least one match on each type locus; (2) minimum mononuclear cell (MNC) count >1×10^7/kg after thawing. Blood type matching was preferred if the HLA type of UCB was identical.

**Conditioning regimen**

All patients were treated with a modified busulfan (BU)/ cyclophosphamide (CY)-based regimen: cytarabine 4 g/m^2/d, -8 d– -7 d; BU 3.2 mg/kg/d, -6 d– -4 d; CY 1.8 g/m^2/d, -3d– -2d; simustine 250 mg/m^2, -2 d; rabbit ATG 2.5 mg/kg/d, -3d– -1d.

**Stem cell source**

Haplo-PBSCs were mobilized using G-CSF (7.5–10 μg/kg/d) from -4 d. The number of PBSCs should meet one of the following criteria: (1) MNC cell count >6–8×10^9/kg (2) CD34^+ cell count ≥5×10^6/kg. If the number of mobilized stem cells on the first day is insufficient, mobilization can be continued on the following day for collection. PBSCs were transfused on d1, and UCB was transfused on d2. Then, UCB was transfused >12 h
after PBSC transfusion, and the MNC cell count in the transfused UCB was 1×10^7/kg.

GVHD prophylaxis and treatment

A triple prophylaxis regimen of cyclosporine A (CsA), short course methotrexate (MTX), and mycophenolate mofetil (MMF) was applied to prevent GVHD. The prophylaxis regimen consisted of the following: CsA (2.5mg/kg/d) was administered intravenously from -9d, and the blood level of CsA was regularly monitored to maintain the minimum blood level range of 200–250 mg L until the patient gradually moved to oral administration; MTX at specific dosages (15 mg/m², +1d; 10 mg/m², +3d, +6d, and +11d); MMF was administered orally at a dosage of 0.5 g twice daily from -9d, halved at +30d, and discontinued at +45d to +60d if GVHD does not occur. Intravenous administration of 2 mg/kg/d methylprednisolone is chosen for GVHD of grade II or higher, followed by a second-line regimen such as CD25 monoclonal antibody for patients who do not respond well to methylprednisolone.

Supportive care and post-transplantation monitoring

Intestinal preparation before transplantation was performed with gentamicin and nystatin administration. Prophylactic antibiotics and antifungals and antivirals were given at the start of the conditioning regimen. After transplantation, bone marrow examinations were performed at least monthly during the first 6 months to assess donor chimerism and relapse. Bone marrow was monitored every 1–1.5 months during the second half-year after transplantation and every 1.5–2 months during the first year post-transplantation.

Definition

Neutrophil engraftment was defined as ANC >0.5×10⁹/L for 3 successive days. Platelet engraftment was defined as PLT >20×10⁹/L for 7 successive days and independent of platelet transfusion. Donor-recipient chimerism >95% was considered a fully donor chimerism. Minimal residual disease (MRD) was defined as the number of leukemic or malignant cells remaining in the patient’s body below the sensitivity of morphological detection when the clearance effect was not achieved after treatment. Multiparameter flow cytometry (MFC) was used to detect MRD with the sensitivity of 10⁻⁵ on bone marrow aspirate samples. Platelet engraftment obtained after 30 days was considered a delayed platelet recovery. Relapse was defined as leukemia cells in peripheral blood or bone marrow >5% or the presence of extramedullary invasion. Deaths due to any cause without recurrence or disease progression were categorized as non-relapse mortality (NRM). Survival in sustained complete remission and without relapse was considered disease-free survival (DFS). GVHD/relapse-free survival (GRFS) was defined as survival without grades III-IV aGVHD and cGVHD requiring systemic therapy, relapse, or disease progression. aGVHD was diagnosed and graded according to the modified Keystone criteria (11). The diagnosis and grading of cGVHD were based on the NIH consensus (12).

Statistical analysis

The deadline for follow-up was January 31, 2022. The primary endpoint was the cumulative incidences of aGVHD. The secondary endpoint was the engraftment, NRM, relapse, cGVHD, overall survival (OS), DFS and GRFS. The normality was assessed on the measurement data; normally distributed data were expressed as \( \bar{X} \pm S \), and non-normally distributed data were expressed as median (range). Statistical data are expressed as examples (%). Overall survival (OS), DFS, and GRFS were estimated using the Kaplan–Meier method. A competing risk model was used to calculate the cumulative incidences of engraftment, GVHD, NRM, and relapse. Graft failure, relapse, and death due to any cause were considered competing risks for GVHD. Death due to any cause was considered a competing risk for engraftment and relapse. For TRM, relapse was considered a competing risk. P<0.05 indicated a statistically significant difference. Survival analysis was performed using the SPSS26.0 software package (SPSS, Chicago, IL, USA), and competing risk analysis was calculated by R software (version 4.1.1) (https://www.r-project.org/).

Results

Patient and donor characteristics

A total of 80 patients were included in this study. The study comprised 42 males and 38 female patients. 38/80 patients had ALL, of which 14 were standard-risk ALL and 24 were high risk, and 42/80 patients had AML/MDS, of which 18 were intermediate-risk and 24 were high-risk. The median follow-up time was 22.4 (range: 2.5–57.8) months. The details are summarized in Table 1.

Engraftment

The median time to neutrophil and platelet engraftment was 13 (range: 8–22) days and 14 (range: 8–103) days, respectively. The 30-day cumulative incidence of neutrophil engraftment was
The cumulative incidence of grades II–IV and grades III–IV aGVHD on day 100 was 26.3%(95%CI: 17.2%–36.3%) and 5.0% (95%CI: 1.6%–11.4%) for all patients, respectively (Figure 1A), 30.9%(95%CI: 17.7%–45.2%) and 4.8%(95%CI: 0.8%–14.3%) for AML/MDS patients, respectively (Figure 1B), and 43.4%(95%CI: 26.8%–58.9%) and 18.8%(95%CI: 8.1%–32.9%) for ALL patients, respectively (Figure 1C).

The estimated cumulative incidence of cGVHD and moderate-severe cGVHD at 3 years was 43.3%(95%CI: 31.6%–54.4%) and 16.0%(95%CI: 8.7%–25.2%), respectively (Figure 2A), 42.6%(95%CI: 26.2%–58.0%) and 12.8%(95%CI: 4.6%–25.5%) for AML/MDS patients, respectively (Figure 2B), and 43.4%(95%CI: 26.8%–58.9%) and 18.8%(95%CI: 8.1%–32.9%) for ALL patients, respectively (Figure 2C).

**Relapse and NRM**

The estimated 3-year cumulative incidence of relapse (CIR) in all patients was 18.8%(95%CI: 10.0%–29.7%) (Figure 3A). The estimated CIR of intermediate- and high-risk AML/MDS was 11.8%(95%CI: 1.8%–31.9%) and 16.5%(95%CI: 3.7%–37.3%), respectively (Figure 3B). The estimated CIR of standard- and high-risk ALL was 20.4%(95%CI: 2.5%–50.1%) and 23.1%(95%CI: 7.8%–43.2%), respectively (Figure 3C).

The estimated 3-year cumulative incidence of NRM in all patients was 17.8%(95%CI: 9.9%–27.5%) (Figure 4A). The estimated NRM of...
standard and high risk ALL was 14.3%(95%CI: 2.1%–37.5%) and 31.5%(95%CI: 13.2%–51.6%), respectively (Figure 4C).

Survival

The estimated 3-year probability of OS in all patients was 77.6%(95%CI: 68.3%–88.1%) (Figure 5A). The estimated OS of intermediate and high risk AML/MDS was 86.3%(95%CI: 70.1%–99.5%) and 76.5%(95%CI: 60.3%–97.1%), respectively (Figure 5B). The estimated OS of standard and high risk ALL was 85.7%(95%CI: 69.2%–99.3%) and 65.2%(95%CI: 46.7%–91.1%), respectively (Figure 5C).

The estimated 3-year probability of DFS in all patients was 63.4%(95%CI: 52.6%–76.5%) (Figure 6A). The estimated DFS of intermediate and high risk AML/MDS was 80.9%(95%CI: 63.4%–99.1%) and 70.4%(95%CI: 52.6%–94.1%), respectively (Figure 6B). The estimated DFS of standard and high risk ALL was 65.3%(95%CI: 42.2%–99.0%) and 45.4%(95%CI: 28.2%–72.9%), respectively (Figure 6C).

The estimated 3-year probability of GRFS in all patients was 55.5%(95%CI: 44.8%–68.7%) (Figure 7A). The estimated GRFS of intermediate and high risk AML/MDS was 64.0%(95%CI: 44.4%–92.2%) and 62.3%(95%CI: 44.3%–87.6%), respectively (Figure 7B). The estimated GRFS of standard and high risk ALL was 59.9%(95%CI: 37.5%–95.7%) and 43.3%(95%CI: 26.8%–69.8%), respectively (Figure 7C).

Discussion

In this study, we reported the outcomes of haplo-cord-PBSCT for the treatment of hematologic malignancies. Due to the addition of UCB, haploidentical peripheral blood transplantation can also achieve a low incidence of GVHD, even when the dose of ATG is reduced to 7.5 mg/kg. Moreover, patients can achieve relatively fast hematopoietic recovery and improved GRFS. Therefore, the current study provided an alternative transplantation option for patients with hematologic malignancies.

Herein, the median time for neutrophil and platelet engraftment was 13 and 14 days, respectively, and the neutrophil and platelet engraftment was 100% and 95%. The Chinese Bone Marrow Transplantation Registration (CRMTR) (13) reported the results of G-CSF/ATG-based haploidentical BM plus PB transplantation; the median time to neutrophil and platelet engraftment was 12 and 17 days, respectively. The neutrophil and platelet engraftment was 96.6% and 94.2%, respectively. In terms of figures alone, our haplo-cord-PBSCT exhibited relatively rapid platelet engraftment and a high rate of engraftment. A meta-analysis study revealed that multiple haplo-HSCT using the PTCY regime achieved a significantly higher engraftment rate in the PB graft than BM graft (14). This was similar to our results; UCB addition may further accelerate engraftment. A rapid engraftment in PB may be associated with higher levels of CD34+ cells than BM. Lyu et al. (15) observed mixed cord blood chimerism in 5.3% of patients in a study of third-party
cord blood-assisted haplo-HSCT. However, all our cases achieved complete haplidentical peripheral blood stem cell engraftment, and no cord blood chimerism was detected. This outcome may be associated with a low MNC cell count in the transfused UCB. In the current study, all the MNC cell count of the transfused UCB was $1 \times 10^7$/kg and CD34+ cells was $3.42 \times 10^4$/kg. It could also be attributed to an interval of more than 12h after the end of the PBSC transfusion before the UCB is transfused. Competition between grafts of different origin is common after double UCB transplantation, resulting in the elimination of one graft. One possible explanation is an immune graft-versus-graft effect. So, the absence of T-cell depletion in haplo-cord-HSCT may also contribute to this result.

Typically, PBSCT results in a high incidence of GVHD (16). However, high GVHD was not observed in our study, and the cumulative incidence of II–IV and III–IV aGVHD was 26.3% and 5%, respectively, and cGVHD and moderate-severe cGVHD was 43.3% and 16.0%, respectively. CBMTR reported the cumulative incidence of II–IV and III–IV aGVHD was 26.7% and 8%, respectively and cGVHD was 42.3% (13). Although we reduced the dose of ATG to 7.5 mg/kg and used PBSC as the graft source, the incidence of GVHD was similar to that of haplidentical BM plus PB transplantation with a standard dose of ATG, suggesting a critical role of UCB. Ma et al. (17) evaluated the outcomes of haplo-PBSCT with the standard dose of ATG, and the cumulative incidence of II–IV and III–IV aGVHD was 30% and 7.5%, respectively, and cGVHD and moderate-severe cGVHD at 1-year was 54.9% and 17.4%, respectively. Based on these data, the incidence of GVHD in haplo-PBSCT was relatively higher even with standard doses of ATG without combined UCB, further suggesting that a key role of UCB in reducing the occurrence of GVHD. Ke et al. (9) suggested that UCB might act as an immunomodulator to regulate the hematopoietic microenvironment. Treg cells play a critical role in modulating immune tolerance after transplantation. Mouse experiments indicated that Treg cells significantly reduce the incidence of GVHD by inducing immune tolerance (18). Another meta-analysis clarified that high Treg cell levels in the graft were associated with low GVHD incidence (19). Treg cells are a major component of the immune system in the fetus, and although declined to adult levels at birth, they still have more immunomodulatory effects than peripheral blood (20). In a mouse model of GVHD, studies have improved GVHD scores by prophylactic injection of third-party cord blood-derived, in vitro expanded Treg cells and recommended phase I trials of prophylactic infusion of third-party Treg cells in double cord blood transplantation (21). It has been reported that compared with PB there are abundant naïve Treg cells in UCB (22). In this study, however, we did not measure naïve Treg cell levels in cord blood. Next, we intend to conduct prospective studies to reveal the mechanism of cord blood. Although our data suggested a crucial role of UCB in the prevention of GVHD, the mechanism of UCB assistance is not yet fully understood, necessitating additional prospective studies and animal experiments to confirm the findings.
In a multicenter randomized controlled study of two ATG doses (7.5mg/kg vs 10mg/kg) of haploidentical BM plus PB transplantation for hematologic malignancies, the 1-year CI of EBV DNAemia was 20.7% and 40.0% in the 7.5 mg/kg and 10.0 mg/kg groups, respectively (P< 0.001), the 1-year CI of CMV DNAemia was 73.4% and 83.4%, respectively (P = 0.038) (23). The results indicated that ATG at 7.5mg/kg was associated with a lower risk of EBV and CMV infection compared to 10.0 mg/kg. However, unlike other hospitals that used plasma as testing sample, our hospital used whole blood. So we didn’t collect data on this and compare them with other hospitals. Next, we plan to do a matching study to confirm this further.

In this study, the estimated 3-year CIR and NRM were 18.8% and 17.8%, respectively. In the above study comparing the two ATG doses, the 3-year CIR was 17.6% and 15.3%, respectively, and the 3-year NRM was 20.2% and 24.4%, respectively (23). John et al. (24) confirmed the lower relapse of cord blood transplantation than haploidentical transplantation by comparing the clinical outcomes of haploidentical transplantation and cord blood transplantation. The proportion of high-risk patients in our study was relatively high but relapse was high, suggesting that haplo-cord-PBSCT may have a strong graft-versus-leukemia (GVL) effect; however, this finding needs to be substantiated with a large sample size in a paired randomized controlled trial.

Our data showed that the estimated 3-year OS, DFS, and GRFS were 77.6%, 77.6%, and 55.5%, respectively. In the above study comparing the two ATG doses, the 3-year OS, DFS, and GRFS was 69.5% vs. 63.5%, 62.2% vs. 60.3%, and 36.0% vs. 31.7% in the 7.5 mg/kg and 10 mg/kg groups, respectively. The outcomes of OS and DFS were comparable to the above values, while GRFS had relatively distinct advantages, wherein patients with long-term disease progression-free and no severe GVHD could have a significantly improved quality of life. A retrospective study have found that cord blood transplantation without ATG has similar incidence of OS, TRM, LFS and GVHD compared with transplantation from unrelated donors, but cord blood transplantation has higher GRFS (25). This further suggests that cord blood plays a key role in our study.

Nevertheless, the present study has some limitations. This was a retrospective study, and no paired samples were available for analysis; hence, comparisons could only be made with historical data. In the next step, we plan to conduct a multicenter prospective control study to confirm the clinical results of haplo-cord-PBSCT and conduct basic studies to further explore the mechanism of UCB.
In conclusion, this study demonstrated the safety and efficacy of haplo-cord-PBSCT for hematological malignancies. The results showed that haplo-cord-PBSCT can achieve relatively rapid hematopoietic recovery and improved GRFS. Moreover, the collection of PBSCs is simpler and more acceptable to donors than BM. Therefore, we considered haplo-cord-PBSCT as an alternative transplantation protocol for the treatment of hematological malignancies. Nonetheless, these findings need to be confirmed by further prospective randomized controlled studies and in-depth studies in conjunction with disease stratification.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

Written informed consent was obtained from the individual(s), and minor(s)’ legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

Author Contributions

Y-JX and CZ conceived and designed the study and helped to draft the manuscript. YC, JH, YL and T-TC performed the data collection. CZ, XM, S-YW and XC performed the statistical analysis. All authors read and critically revised the manuscript for intellectual content and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (No.81974002), Translational Research Grant of NCRCH (No. 2021WWC02).

Acknowledgments

We thank all of the physicians, nurses for their unevaled contribution to this study, and patients for participating in this research.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References

1. Xu LP, Lu PH, Wu DP, Sun ZM, Liu QF, Han MZ, et al. Hematopoietic stem cell transplantation activity in China 2019: A report from the Chinese bone and marrow transplantation registry group. Bone Marrow Transplant (2021) 56(12):2940–7. doi: 10.1038/s41409-021-01431-6

2. Pasoweg IR, Baldemero H, Chabannon C, Basak GW, de La Cámara R, Corbacioglu S, et al. Hematopoietic stem cell transplantation and cellular therapy survey of the EBMT: Monitoring of activities and trends over 30 years. Bone Marrow Transplant (2021) 56(7):1651–64. doi: 10.1038/s41409-021-01227-8

3. Ruggert A, Labopin M, Bacigalupo A, Gulhus Z, Koe Y, Blaise D, et al. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. Cancer (2018) 124(7):1428–37. doi: 10.1002/cncr.31228

4. Mehta RS, Saliba RM, Alfeldt LC, Jorgensen JL, Wang SA, Anderlini P, et al. Bone marrow versus peripheral blood grafts for haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide. Transplantation (2021) 27(12):1003.e1–1003.e13. doi: 10.1097/TC.T.0000000000001903

5. Mariotti J, Devillier R, Bramanti S, Giordano L, Sarina B, Furst S, et al. Peripheral blood stem cells versus bone marrow for T cell-replete haploidentical transplantation with post-transplant cyclophosphamide in Hodgkin lymphoma. Bone Marrow Transplant (2019) 25(9):1810–7. doi: 10.1038/s41409-020-0821-9

6. Ma YR, Zhang X, Xu L, Wang Y, Yan C, Chen H, et al. G-CSF-Primed peripheral blood stem cells with haploidentical transplantation could achieve satisfactory clinical outcomes for acute leukemia patients in the first complete remission. A registered study. Front Oncol (2021) 11:631625. doi: 10.3389/fonc.2021.631625

7. Harada K, Fuji S, Sen S, Kanda J, Ueki T, Kimura F, et al. Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant (2020) 55(6):1197–9. doi: 10.1038/s41409-019-0666-2

8. Xu J, Zhao R, Yang L, Gong H, Ma S, Chen J, et al. Haploidentical stem cells combined with a small dose of umbilical cord blood transplantation exert similar survival outcome of HLA-matched stem cells transplantation in T-cell acute lymphoblastic leukemia. Bone Marrow Transplant (2020) 55(6):1197–9. doi: 10.1038/s41409-020-0821-9

9. Ke P, Bao XB, Hu XH, Zhuang J, Wu XJ, Liu YJ, et al. Myeloablative conditioning regimens with combined of haploidentical and cord blood transplantation for myelodysplastic syndrome patients. Bone Marrow Transplant (2018) 53(2):162–8. doi: 10.1038/bmt.2017.229

10. Liu L, Zhang Y, Jiao W, Zhou H, Wang Q, Qiu H, et al. Combination of haploidentical hematopoietic stem cell transplantation with an unrelated cord-blood unit in patients with severe aplastic anemia: A report of 146 cases. Bone Marrow Transplant (2020) 55(10):2017–25. doi: 10.1038/s41409-020-0874-9

11. Przepiorka D, Wieden D, Martin P, Klingemann HG, Beatty P, Howes J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant (1995) 15(6):825–8.

12. Jagasai MH, Greinix HT, Arora M, Williams KM, Wolf D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-Host disease: I. the 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant (2015) 21(3):389–401.e1. doi: 10.1016/j.bbmt.2014.12.001

13. Tang F, Xu Y, Chen H, Xu L, Zhang X, Wang Y, et al. Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide. Results from the Chinese bone marrow transplantation registry group (CBMTRG). Sci China Life Sci (2020) 63(4):571–81. doi: 10.1007/s11427-019-9594-7

14. Arcuri LJ, Hamerschlag N, Rocha V, Bonfim C, Kerbawy MN. Outcomes after haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide: A systematic review and meta-analysis comparing myeloablative with reduced-intensity conditioning regimens and bone marrow with peripheral blood stem cell grafts. Transplant Cell Ther (2021) 27(9):782.e1–7. doi: 10.1016/j.jtct.2021.06.011

15. Lu Y, Lu W, Yao J, Xiao X, Li Q, Wang J, et al. Comparison of outcomes of haploidentical donor hematopoietic stem cell transplantation supported by third-party cord blood with HLA-matched unrelated donor transplantation. Leuk Lymphoma (2020) 61(4):840–7. doi: 10.1080/10428194.2019.1695055

16. Yu X, Liu L, Xie Z, Dong C, Zhao L, Zhang J, et al. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-a systematic review and meta-analysis. Crit Rev Oncol Hematol (2019) 133:120–8. doi: 10.1016/j.critrevonc.2018.05.017

17. Ma YR, Zhang X, Xu L, Wang Y, Yan C, Chen H, et al. G-CSF-Primed peripheral blood stem cell haploidentical transplantation could achieve satisfactory clinical outcomes for acute leukemia patients in the first complete remission. Front Oncol (2021) 11:631625. doi: 10.3389/fonc.2021.631625

18. Ganguly S, Ross DB, Panoskaltsis-Mortari A, Kanakery CG, Blazar BR, Levy RB, et al. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood (2014) 124(13):2314–41. doi: 10.1182/blood-2013-10-525873

19. Fisher SA, Lamikanra A, Dorie C, Gration B, Tsang P, Danby RD, et al. Increased regulatory T cell graft content is associated with improved outcome in haematopoietic stem cell transplantation: A systematic review. Br J Haematol (2017) 176(3):448–63. doi: 10.1111/bjh.14433

20. Hao L, Gao I, Chen XH, Zou ZM, Zhang X, Kong PY, et al. Human umbilical cord blood-derived stromal cells prevent graft-versus-host disease in mice following haplo-identical stem cell transplantation. Cytotherapy (2011) 13(1):83–91. doi: 10.3109/14653249.2010.501786

21. Parmar S, Liu X, Tung SS, Robinson SN, Rodrigue G, Cooper LJN, et al. Third-party umbilical cord blood-derived regulatory T cells prevent xenograft graft-versus-host disease. Cytotherapy (2014) 16(1):90–100. doi: 10.1016/j.jcyt.2013.07.009

22. Kim YJ, Broxmeyer HE. Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance. Crit Rev Oncol Hematol (2011) 79(2):112–26. doi: 10.1016/j.critrevonc.2010.07.009

23. Lin R, Wang Y, Huang F, Fan Z, Zhang S, Yang T, et al. Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: A multicenter randomized study. BMC Med (2019) 17(1):136. doi: 10.1186/s12916-019-1393-7

24. Wagner JE, Ballen KK, Zhang MJ, Albbe-Johnson M, Karanes C, Milano F, et al. Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning. Blood Adv (2021) 5(20):4064–72. doi: 10.1182/bloodadvances.2021004462

25. Tong J, Xuan L, Sun Y, Huang D, Liu H, Zheng C, et al. Umbilical cord blood transplantation without antithymocyte globulin results in similar survival but better quality of life compared with unrelated peripheral blood stem cell transplantation for the treatment of acute leukemia-a retrospective study in China. Biol Blood Marrow Transplant (2017) 23(9):1541–8. doi: 10.1016/j.bbmt.2017.05.004